Literature DB >> 6846402

Fragile (X) X-linked mental retardation I: relationship between age and intelligence and the frequency of expression of fragil (X)(q28).

A E Chudley, J Knoll, J W Gerrard, L Shepel, E McGahey, J Anderson.   

Abstract

Members of eight Saskatchewan families with fragile (X) X-linked mental retardation were studied in an attempt to relate frequency to age and intelligence. The mean IQ of 37 affected men was 35 (range 10-66). The mean IQ of 32 carriers was 88 (range 57-119), and the mean IQ of 13 females who remain at risk for being carriers, have no affected sons, and who failed to demonstrate the fra(X) was 100 (range 78-126). We demonstrated a significant inverse relationship between age and frequency of the fra(X) in carriers and in affected males. However, we demonstrated a more highly significant inverse relationship between frequency of the fra(X) and IQ in carriers but to a lesser extent in affected males. Of 32 carriers, only 3 (9.4%) did not demonstrate the fra(X) after addition of 5-fluoro-2'-deoxyuridine (FUdR) to the folic acid and thymidine-reduced culture medium. From these data we would recommend that chromosome studies in individuals at risk for fra(X) X-linked mental retardation be carried out at the youngest age and that the addition of FUdR to culture medium is useful in carrier identification. It is clear that, in at least the carriers, a lower expression of the fra(X) is highly significantly correlated to higher intelligence.

Entities:  

Mesh:

Year:  1983        PMID: 6846402     DOI: 10.1002/ajmg.1320140412

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  18 in total

1.  No significant relationship between age and frequency of chromosome lesions in mentally retarded individuals with or without the fragile X syndrome.

Authors:  M G Butler
Journal:  Hum Genet       Date:  1990-01       Impact factor: 4.132

2.  Mental status of females with an FMR1 gene full mutation.

Authors:  B B de Vries; A M Wiegers; A P Smits; S Mohkamsing; H J Duivenvoorden; J P Fryns; L M Curfs; D J Halley; B A Oostra; A M van den Ouweland; M F Niermeijer
Journal:  Am J Hum Genet       Date:  1996-05       Impact factor: 11.025

3.  The fragile X syndrome in a large family. I. Cytogenetic and clinical investigations.

Authors:  H Veenema; J P Geraedts; G C Beverstock; P L Pearson
Journal:  J Med Genet       Date:  1987-01       Impact factor: 6.318

4.  Non-specific X-linked mental retardation with fragile X chromosome: somatic features, cytogenetic diagnosis and elements for genetic counselling.

Authors:  M A de Arce; E Law; J G Masterson
Journal:  Ir J Med Sci       Date:  1983-12       Impact factor: 1.568

5.  Frequency and replication status of the fragile X, fra(X)(q27-28), in a pair of monozygotic twins of markedly differing intelligence.

Authors:  E Tuckerman; T Webb; S E Bundey
Journal:  J Med Genet       Date:  1985-04       Impact factor: 6.318

6.  A community study of severe mental retardation in the West Midlands and the importance of the fragile X chromosome in its aetiology.

Authors:  S Bundey; T P Webb; A Thake; J Todd
Journal:  J Med Genet       Date:  1985-08       Impact factor: 6.318

Review 7.  The fragile X syndrome: the patients and their chromosomes.

Authors:  M A De Arce; A Kearns
Journal:  J Med Genet       Date:  1984-04       Impact factor: 6.318

8.  Cytogenetic investigations in mentally retarded and normal males from 14 families with the fragile site at Xq28. Results of folic acid treatment on fra(X) expression.

Authors:  K B Nielsen; N Tommerup
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

9.  Manifestation of the fragile site Xq27 in fibroblasts. III. A method to demonstrate R-type replication patterns and the fragile site.

Authors:  G Barbi; P Steinbach; A Wiedenmann; W Vogel
Journal:  Hum Genet       Date:  1983       Impact factor: 4.132

10.  Mean corpuscular hemoglobin is increased in Martin-Bell syndrome.

Authors:  U Langenbeck; J Schmidtke; I Bartels; I Hansmann; H Knüppel
Journal:  Hum Genet       Date:  1984       Impact factor: 4.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.